{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"29.8","value":"12.2"}]}],"title":"DOR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.9","upperLimit":"31.1","value":"13.5"}]}],"title":"PFS"},{"categories":[{"measurements":[{"comment":"The 95% upper confidence limits for median overall survival could not be calculated because of the high number/proportion (11 participants/44%) of participants alive at the time of the analysis.","groupId":"OG000","lowerLimit":"22.7","upperLimit":"NA","value":"35.1"}]}],"title":"OS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Calculated median DOR, PFS, OS","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received NYESO-1ᶜ²⁵⁹T following ASCT","id":"OG000","title":"NYESO-1ᶜ²⁵⁹T Cells"}],"paramType":"MEDIAN","populationDescription":"Participants who received NYESO-1ᶜ²⁵⁹T following ASCT","reportingStatus":"POSTED","timeFrame":"DOR: Initial date of response to date of progressive disease or death PFS: Date of first T -cell infusion to earliest date of disease progression of death due to any cause OS: Date of first T-cell infusion to date of death from any cause.","title":"Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"median months"}